Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries - Articles - Dermatology · Immunology · Rheumatology

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Rheumatoid Arthritis

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Semin Arthritis Rheum

Zhang Q, McDermott GC, Juge PA, Chang SH, Vanni KM, Qian G, Bade KJ, Mueller KT, Kowalski EN, Saavedra AA, Sparks JA

doi: 10.1016/j.semarthrit.2024.152561

Rheumatoid Arthritis

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Ann Rheum Dis

Lend K, Lampa J, Padyukov L, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Rudin A, Østergaard M, Haavardsholm EA, Hørslev-Petersen K, Uhlig T, Sokka-Isler T, Gudbjornsson B, Grondal G, Frazzei G, Christiaans J, Wolbink G, Rispens T, Twisk JWR, van Vollenhoven RF

doi: 10.1136/ard-2024-226024

Rheumatoid Arthritis

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Lancet Rheumatol

Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB

doi: 10.1016/S2665-9913(24)00221-2

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Psoriatic ArthritisRheumatoid Arthritis

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Ann Rheum Dis

Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M, Blanco-Madrigal JM, Manrique-Arija S, Perez-Pampin E, Ruiz-Montesino D, Sánchez-Alonso F, Sanchez-Piedra C, Castrejón I, BIOBADASER Study Group

doi: 10.1136/ard-2023-225271

Rheumatoid Arthritis

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Rheumatol Ther

Taylor PC, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B, Alten R, Nash P, Feist E

doi: 10.1007/s40744-024-00732-8

Rheumatoid Arthritis

Quantitative Computed Tomography Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease

Chest

Humphries SM, Adegunsoye A, Demoruelle MK, Wei Kam ML, Amigues I, Bang TJ, Teague SD, Lynch DA, Chung JH, Strek ME, Swigris JJ, Solomon JJ

doi: 10.1016/j.chest.2024.10.052

Rheumatoid Arthritis

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study

Rheumatology (Oxford)

López-Medina C, Gorlier C, Orbai AM, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Meisalu S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L

doi: 10.1093/rheumatology/keaf002

Related content

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Quantitative Computed Tomography Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study